(Image source: eyeworld.org) Allergan, Inc. (NYSE:AGN) received a court victory yesterday after a Texas judge upheld its patent for the drug Lumigan, which treats glaucoma. Generic drug makers were seeking to product generic versions of the drug. The court ruling upholds Allergan’s patent for Lumigan until 2027. Allergan now has exclusive control over the glaucoma drug.